Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04179110
Title Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Yale University
Indications

urethra transitional cell carcinoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

Therapies

Pembrolizumab + Ramucirumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.